Report Company Directory
- CohBar Reports Second Quarter 2023 Financial Results by GlobeNewsWire
- Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) by GlobeNewsWire
- Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting by GlobeNewsWire
- CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy by GlobeNewsWire
- CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress by GlobeNewsWire
- CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022 by GlobeNewsWire
- CohBar Announces Reverse Stock Split by GlobeNewsWire
- CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference by GlobeNewsWire
- CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress by GlobeNewsWire
- CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022 by GlobeNewsWire